Trending
Overcoming Formulation Challenges in Sterile Peptide Injectables and Complex Therapeutics
Xseer Pharmaceuticals is a 503B outsource compoun...
Optimizing Metabolic Protocols: The Synergistic Role of Levocarnitine, L-Arginine, and Active B12
Xseer Pharmaceuticals is a 503B outsource compoun...
FDA Proposes Exclusion of GLP-1s from the 503B Bulks List: Implications for Outsourcing Facilities
Xseer Pharmaceuticals is a 503B outsource compoun...
Latest News
Optimizing Metabolic Protocols: The Synergistic Role of Levocarnitine, L-Arginine, and Active B12
Medical weight management continues to evolve as p...
Overcoming Formulation Challenges in Sterile Peptide Injectables and Complex Therapeutics
Peptide therapeutics and complex coenzymes represe...
FDA Proposes Exclusion of GLP-1s from the 503B Bulks List: Implications for Outsourcing Facilities
The U.S. Food and Drug Administration (FDA) contin...
January 07, 2024
3973
Where we are
Xseer Pharmaceuticals is a 503B outsource compounding facility, FDA-registered, in quality-compliant manufacturing of sterile injectables.
With our facility located in California, we are currently preparing to submit our California Outsourcing Facility application.
Tags:
